LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.
Patients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.
Both groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.
Phase:
PHASE3
Details
Lead Sponsor:
Fundaci Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators:
Fundacin CITA Alzheimer Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa Hospital Universitario Marqus de Valdecilla University Hospital Virgen de las Nieves